A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Completed · Phase 1 · NCT03625505
Conditions: Acute Myeloid Leukemia (AML)
At a glance
- Research payments reported, 2025
- $27,592
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 61
About the trial
- Sponsor
- AbbVie (with Astellas Pharma Inc, Genentech, Inc.)
- Tested
- Venetoclax (drug), Gilteritinib (drug)
- Dates
- Started 2018-10-18; completion 2021-08-31
- Results posted
- Not yet
A dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK) and efficacy of venetoclax, in combination with gilteritinib, in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) who have failed to respond to, and/or have relapsed or progressed after at least 1 prior therapy.
From ClinicalTrials.gov, last updated 2021-09-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $27,592 in research payments for this study in 2025 (1 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.